Cover Image
市場調查報告書

隱形眼鏡:醫療設備的開發平台評估

Contact Lenses - Medical Devices Pipeline Assessment, 2016

出版商 GlobalData 商品編碼 356608
出版日期 內容資訊 英文 172 Pages
訂單完成後即時交付
價格
Back to Top
隱形眼鏡:醫療設備的開發平台評估 Contact Lenses - Medical Devices Pipeline Assessment, 2016
出版日期: 2016年04月01日 內容資訊: 英文 172 Pages
簡介

本報告提供全球隱形眼鏡市場上,主要開發中產品與臨床實驗的進展調查,產品特性比較分析 (臨床實驗的各進行階段) ,再加上主要企業簡介及代表性產品,近來的市場動靜 (新產品開發、認證,業績趨勢等) 的資訊彙整,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 隱形眼鏡概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各市場區隔
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 開發中產品:現在臨床實驗中的產品

第4章 臨床實驗中的開發中產品:各企業

  • 隱形眼鏡的企業:各臨床實驗階段的開發中產品
  • 隱形眼鏡:各臨床實驗階段的開發中產品

第5章 隱形眼鏡市場:企業、產品概要

  • Aeon Astron Corporation
    • 開發中產品及進行中的臨床實驗概要
  • Alcon, Inc.
  • Apeliotus Ophthalmics
  • Auburn University
  • Axcelon Biopolymers Corp.
  • Bausch & Lomb Incorporated
  • Body Organ Biomedical Corp.
  • Children's Hospital Boston
  • CooperVision, Inc.
  • EP Global Communications, Inc.
  • Euclid Systems Corporation
  • Eyenovations
  • EyeYon Medical
  • Imperial College London
  • Johnson & Johnson Vision Care, Inc.
  • Massachusetts Eye and Ear Infirmary
  • Novartis AG
  • Ocular Dynamics, LLC
  • Ocutec Limited
  • Presbia Plc
  • Stanford University
  • The Hong Kong University of Science and Technology
  • The University of New South Wales
  • UltraVision CLPL
  • University of California, San Diego
  • University of Florida
  • University of Valencia
  • University of Washington
  • University of Western Ontario
  • Valeant Pharmaceuticals International, Inc.
  • Visioneering Technologies, Inc.
  • VISTAKON Pharmaceuticals, LLC
  • Yolia Health

第6章 隱形眼鏡市場:目前的趨勢 (共54件)

第7章 附錄

圖表一覽

目錄
Product Code: GDME0169EPD

GlobalData's Medical Devices sector report, "Contact Lenses - Medical Devices Pipeline Assessment, 2016" provides an overview of Contact Lenses currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Contact Lenses pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Contact Lenses under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Contact Lenses and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Contact Lenses under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Contact Lenses Overview

3. Products under Development

  • 3.1. Contact Lenses - Pipeline Products by Stage of Development
  • 3.2. Contact Lenses - Pipeline Products by Segment
  • 3.3. Contact Lenses - Pipeline Products by Territory
  • 3.4. Contact Lenses - Pipeline Products by Regulatory Path
  • 3.5. Contact Lenses - Pipeline Products by Estimated Approval Date
  • 3.6. Contact Lenses - Ongoing Clinical Trials

4. Contact Lenses - Pipeline Products under Development by Companies

  • 4.1. Contact Lenses Companies - Pipeline Products by Stage of Development
  • 4.2. Contact Lenses - Pipeline Products by Stage of Development

5. Contact Lenses Companies and Product Overview

  • 5.1. Aeon Astron Corporation Company Overview
    • 5.1.1. Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Alcon, Inc. Company Overview
    • 5.2.1. Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Apeliotus Ophthalmics Company Overview
    • 5.3.1. Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Auburn University Company Overview
    • 5.4.1. Auburn University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Axcelon Biopolymers Corp. Company Overview
    • 5.5.1. Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Bausch & Lomb Incorporated Company Overview
    • 5.6.1. Bausch & Lomb Incorporated Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Body Organ Biomedical Corp. Company Overview
    • 5.7.1. Body Organ Biomedical Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. Children's Hospital Boston Company Overview
    • 5.8.1. Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. CooperVision, Inc. Company Overview
    • 5.9.1. CooperVision, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. EP Global Communications, Inc. Company Overview
    • 5.10.1. EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Euclid Systems Corporation Company Overview
    • 5.11.1. Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Eyenovations Company Overview
    • 5.12.1. Eyenovations Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. EyeYon Medical Company Overview
    • 5.13.1. EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. Imperial College London Company Overview
    • 5.14.1. Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. Johnson & Johnson Vision Care, Inc. Company Overview
    • 5.15.1. Johnson & Johnson Vision Care, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. Massachusetts Eye and Ear Infirmary Company Overview
    • 5.16.1. Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. Novartis AG Company Overview
    • 5.17.1. Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Ocular Dynamics, LLC Company Overview
    • 5.18.1. Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. Ocutec Limited Company Overview
    • 5.19.1. Ocutec Limited Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. Presbia Plc Company Overview
    • 5.20.1. Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21. Stanford University Company Overview
    • 5.21.1. Stanford University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22. The Hong Kong University of Science and Technology Company Overview
    • 5.22.1. The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23. The University of New South Wales Company Overview
    • 5.23.1. The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24. UltraVision CLPL Company Overview
    • 5.24.1. UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25. University of California, San Diego Company Overview
    • 5.25.1. University of California, San Diego Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26. University of Florida Company Overview
    • 5.26.1. University of Florida Pipeline Products & Ongoing Clinical Trials Overview
  • 5.27. University of Valencia Company Overview
    • 5.27.1. University of Valencia Pipeline Products & Ongoing Clinical Trials Overview
  • 5.28. University of Washington Company Overview
    • 5.28.1. University of Washington Pipeline Products & Ongoing Clinical Trials Overview
  • 5.29. University of Western Ontario Company Overview
    • 5.29.1. University of Western Ontario Pipeline Products & Ongoing Clinical Trials Overview
  • 5.30. Valeant Pharmaceuticals International, Inc. Company Overview
    • 5.30.1. Valeant Pharmaceuticals International, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.31. Visioneering Technologies, Inc. Company Overview
    • 5.31.1. Visioneering Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.32. VISTAKON Pharmaceuticals, LLC Company Overview
    • 5.32.1. VISTAKON Pharmaceuticals, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.33. Yolia Health Company Overview
    • 5.33.1. Yolia Health Pipeline Products & Ongoing Clinical Trials Overview

6. Contact Lenses- Recent Developments

  • 6.1. Mar 03, 2016: The Cooper Companies Announces First Quarter 2016 Results
  • 6.2. Mar 01, 2016: First Patients in Presbia Microlens FDA Study Complete 12-Month Postoperative Visits
  • 6.3. Feb 19, 2016: Strong growth in revenue and earnings Essilor focused on its 2018 objectives
  • 6.4. Feb 12, 2016: Carl Zeiss Meditec Grows, Boosted by Currency Tailwinds / Strongest Growth Once Again in Surgical Ophthalmology
  • 6.5. Feb 05, 2016: Briefing Summary of the Analyst/Investor Meeting for the 3rd Quarter Financial Results for the Fiscal Year Ending March 31, 2016 Tokyo, January 29, 2016
  • 6.6. Jan 29, 2016: Hoya Reports Third Quarter Results; Record Nine Months Results
  • 6.7. Jan 27, 2016: Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
  • 6.8. Jan 15, 2016: HOYA Presents Hoya EyeGenius
  • 6.9. Dec 16, 2015: AEA Investors to Acquire Majority Stake in 1-800 Contacts from Thomas H. Lee Partners
  • 6.10. Dec 16, 2015: Carl Zeiss Meditec increases revenue to € 1,040 million / Market shares expanded in a number of markets
  • 6.11. Dec 03, 2015: The Cooper Companies Announces Fourth Quarter and Full Year 2015 Results
  • 6.12. Nov 10, 2015: Bausch + Lomb Announces 2016 Launch of Bausch + Lomb ULTRA Contact Lenses for Presbyopia
  • 6.13. Nov 09, 2015: Unicon Optical to Acquire Taiwan-Based Contact Lenses Company
  • 6.14. Nov 06, 2015: Shanghai Conant Optics Plans to Raise up to USD188.6 Million in Private Placement of Shares
  • 6.15. Oct 27, 2015: Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
  • 6.16. Oct 26, 2015: Valeant Pharma Receives FTC Voluntary Request Letter Related To Paragon Holdings Acquisition
  • 6.17. Oct 12, 2015: EPGL to Grant CooperVision Exclusive Licenses in Exchange for Royalties and Compensation Agreement by November 6, 2015
  • 6.18. Oct 08, 2015: Robins Kaplan LLP Named Co-Lead Counsel in Disposable Contact Lens Antitrust Litigation
  • 6.19. Oct 05, 2015: Presbia Introduces Time-Saving Disposable Microlens Inserter
  • 6.20. Sep 17, 2015: Presbia Flexivue Microlens Implanted in More Than 1,000 Patients Worldwide
  • 6.21. Sep 17, 2015: QSpex Technologies Enters into Agreement with Shanghai Conant Optical
  • 6.22. Sep 14, 2015: HOYA Vision Care Establishes Subsidiary in Turkey
  • 6.23. Sep 10, 2015: Presbia Completes Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens
  • 6.24. Sep 10, 2015: Johnson & Johnson Vison Care Launches New Lens With A Tear-Infused Design
  • 6.25. Sep 03, 2015: Presbia to Complete Second Stage Enrollment in the US FDA Pivotal Study of Presbia Flexivue Microlens
  • 6.26. Sep 03, 2015: The Cooper Companies Announces Third Quarter 2015 Results
  • 6.27. Aug 24, 2015: Results of Patient Outcomes Outside of the U.S. Demonstrate Safety and Effectiveness of Presbia Flexivue Mircolens
  • 6.28. Aug 10, 2015: Presbia Surpasses Treatment of 300 Subjects as Part of the US FDA Pivotal Study Enrollment
  • 6.29. Aug 05, 2015: Essilor International Raises USD328.4 Million in Public Offering of Notes Due 2017
  • 6.30. Aug 03, 2015: Xavier Galliot, Chief Sustainability Officer of the Essilor Group
  • 6.31. Jul 30, 2015: Essilor of America to Acquire Vision Source from Brazos Private Equity
  • 6.32. Jul 30, 2015: Essilor Announces Strong results ; A winning strategy
  • 6.33. Jul 29, 2015: Hoya Announces First Quarter Results Ended June 30, 2015
  • 6.34. Jul 29, 2015: Hoya Reports First Quarter Financial Results
  • 6.35. Jul 28, 2015: Valeant Pharmaceuticals Presented with Economic Development Support from Rochester Gas & Electric for the Bausch + Lomb ULTRA Contact Lens Manufacturing Line Expansion in Rochester, NY
  • 6.36. Jul 21, 2015: Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches
  • 6.37. Jul 13, 2015: Valeant Pharma to Acquire Unilens Vision
  • 6.38. Jul 09, 2015: Presbia Reaches the Halfway Mark in Second Stage Enrollment in the US FDA Pivotal Study
  • 6.39. Jun 23, 2015: Bausch + Lomb's Biotrue ONEday for Presbyopia Contact Lenses Now Available in Expanded High Add Powers
  • 6.40. Jun 22, 2015: Visioneering Technologies Taps MidSouth Premier Ophthalmics as Exclusive Distributor for NaturalVue Lenses
  • 6.41. Jun 04, 2015: The Cooper Companies Announces Second Quarter 2015 Results
  • 6.42. Jun 01, 2015: NVISION Eye Centers Performs First KAMRA Inlay in California
  • 6.43. May 15, 2015: Ultravision Expands Licensing Agreement with Art Optical
  • 6.44. May 14, 2015: Unilens Vision Reports Third Quarter Operating Results
  • 6.45. May 12, 2015: Hoya Reports Fourth Quarter Results; Achieves Record Annual Sales and Profit
  • 6.46. May 04, 2015: NVISION Eye Centers Becomes One of the First in the U.S. to Offer Breakthrough KAMRA Inlay for Near Vision Loss Associated With Aging
  • 6.47. May 03, 2015: Bausch + Lomb Presents New Scientific and Clinical Research During the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, CO
  • 6.48. Apr 23, 2015: Novartis delivered sales growth, significant margin expansion and strong innovation in Q1; now with a more focused portfolio
  • 6.49. Apr 21, 2015: Presbia Announces the Start of Commercialization of the Presbia Flexivue Micolens in Australia
  • 6.50. Apr 21, 2015: Revenue up very sharply by 25.4% Annual targets confirmed
  • 6.51. Apr 18, 2015: Durrie Vision First in Region to Provide Corneal Implant Designed to Treat Presbyopia
  • 6.52. Apr 18, 2015: ZEISS Showcases Integrated Solutions that Deliver Faster Practice and Surgical Workflow and Address Critical Diagnostic Challenges
  • 6.53. Apr 17, 2015: FDA approves first-of-its-kind corneal implant to improve near vision in certain patients
  • 6.54. Apr 16, 2015: Visioneering Technologies Introduces NaturalVue 1 Day Multifocal Contact Lens Works with the Brain to Optimize Vision

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Contact Lenses - Pipeline Products by Stage of Development
  • Table 2: Contact Lenses - Pipeline Products by Segment
  • Table 3: Contact Lenses - Pipeline Products by Territory
  • Table 4: Contact Lenses - Pipeline Products by Regulatory Path
  • Table 5: Contact Lenses - Pipeline Products by Estimated Approval Date
  • Table 6: Contact Lenses - Ongoing Clinical Trials
  • Table 7: Contact Lenses Companies - Pipeline Products by Stage of Development
  • Table 8: Contact Lenses - Pipeline Products by Stage of Development
  • Table 9: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: Body Organ Contact Lens - Product Status
  • Table 11: Body Organ Contact Lens - Product Description
  • Table 12: Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 13: Dailies Total 1 Colors SiHy Lens - Product Status
  • Table 14: Dailies Total 1 Colors SiHy Lens - Product Description
  • Table 15: Dailies Total 1 Multifocal SiHy Lens - Product Status
  • Table 16: Dailies Total 1 Multifocal SiHy Lens - Product Description
  • Table 17: Dailies Total 1 Toric SiHy Lens - Product Status
  • Table 18: Dailies Total 1 Toric SiHy Lens - Product Description
  • Table 19: Smart Lens - Diabetes - Product Status
  • Table 20: Smart Lens - Diabetes - Product Description
  • Table 21: Weekly WG SiHy Lens - Product Status
  • Table 22: Weekly WG SiHy Lens - Product Description
  • Table 23: Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: Comfort Lens - Product Status
  • Table 25: Comfort Lens - Product Description
  • Table 26: Contact Lens - Glaucoma - Product Status
  • Table 27: Contact Lens - Glaucoma - Product Description
  • Table 28: Auburn University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 29: Smart Contact Lenses - Product Status
  • Table 30: Smart Contact Lenses - Product Description
  • Table 31: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 32: MC - PHEMA Based Contact Lens - Product Status
  • Table 33: MC - PHEMA Based Contact Lens - Product Description
  • Table 34: Bausch & Lomb Incorporated Pipeline Products & Ongoing Clinical Trials Overview
  • Table 35: Ultra Multi Focal Lens - Product Status
  • Table 36: Ultra Multi Focal Lens - Product Description
  • Table 37: Ultra Plus Powers Lens - Product Status
  • Table 38: Ultra Plus Powers Lens - Product Description
  • Table 39: Ultra Toric Lens - Product Status
  • Table 40: Ultra Toric Lens - Product Description
  • Table 41: Body Organ Biomedical Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 42: Biolens - Product Status
  • Table 43: Biolens - Product Description
  • Table 44: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
  • Table 45: Contact Lens Drug Delivery Device - Product Status
  • Table 46: Contact Lens Drug Delivery Device - Product Description
  • Table 47: CooperVision, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 48: SiH Multifocal - Product Status
  • Table 49: SiH Multifocal - Product Description
  • Table 50: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 51: EP Global Contact Lens - Product Status
  • Table 52: EP Global Contact Lens - Product Description
  • Table 53: Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 54: Drug-Eluting Contact Lenses - Product Status
  • Table 55: Drug-Eluting Contact Lenses - Product Description
  • Table 56: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview
  • Table 57: Drug Dispensing Contact Lens - Product Status
  • Table 58: Drug Dispensing Contact Lens - Product Description
  • Table 59: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview
  • Table 60: Hyper-CL - Product Status
  • Table 61: Hyper-CL - Product Description
  • Table 62: EyeYon Medical - Ongoing Clinical Trials Overview
  • Table 63: Hyper-CL - Prospective, Randomized Crossover Study of Using the Hyper-CL Lens (Hyper Osmotic Contact Lens) in Subjects Suffering from Corneal Edema
  • Table 64: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
  • Table 65: Contact Lens - Product Status
  • Table 66: Contact Lens - Product Description
  • Table 67: Johnson & Johnson Vision Care, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 68: 1-DAY ACUVUE Multifocal Contact Lens - Product Status
  • Table 69: 1-DAY ACUVUE Multifocal Contact Lens - Product Description
  • Table 70: Anti-allergic Contact Lens - Product Status
  • Table 71: Anti-allergic Contact Lens - Product Description
  • Table 72: Next Generation 1-DAY ACUVUE DEFINE Contact Lens - Product Status
  • Table 73: Next Generation 1-DAY ACUVUE DEFINE Contact Lens - Product Description
  • Table 74: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview
  • Table 75: Therapeutic Contact Lens - Product Status
  • Table 76: Therapeutic Contact Lens - Product Description
  • Table 77: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 78: CLM041 - Product Status
  • Table 79: CLM041 - Product Description
  • Table 80: Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 81: Contact Lens - Dry Eye Disease - Product Status
  • Table 82: Contact Lens - Dry Eye Disease - Product Description
  • Table 83: Ocutec Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 84: Third PEG Hydrogel Contact Lens - Product Status
  • Table 85: Third PEG Hydrogel Contact Lens - Product Description
  • Table 86: Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 87: Flexivue Microlens - Product Status
  • Table 88: Flexivue Microlens - Product Description
  • Table 89: Presbia Plc - Ongoing Clinical Trials Overview
  • Table 90: Flexivue Microlens - A Phase II trial of Presbia Flexivue Microlens for The Treatment of Presbyopia
  • Table 91: Flexivue Microlens - Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes
  • Table 92: Stanford University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 93: Polymer Network Hydrogel Contact Lens - Product Status
  • Table 94: Polymer Network Hydrogel Contact Lens - Product Description
  • Table 95: The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview
  • Table 96: Resonance Circuit Sensor Contact Lens - Product Status
  • Table 97: Resonance Circuit Sensor Contact Lens - Product Description
  • Table 98: The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview
  • Table 99: Stem Cell Contact Lens - Product Status
  • Table 100: Stem Cell Contact Lens - Product Description
  • Table 101: UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview
  • Table 102: Contact Lenses - Product Status
  • Table 103: Contact Lenses - Product Description
  • Table 104: University of California, San Diego Pipeline Products & Ongoing Clinical Trials Overview
  • Table 105: Aerated Contact Lens - Product Status
  • Table 106: Aerated Contact Lens - Product Description
  • Table 107: Telescopic Contact Lens - Product Status
  • Table 108: Telescopic Contact Lens - Product Description
  • Table 109: University of Florida Pipeline Products & Ongoing Clinical Trials Overview
  • Table 110: Vitamin E - Packed Lenses - Product Status
  • Table 111: Vitamin E - Packed Lenses - Product Description
  • Table 112: University of Valencia Pipeline Products & Ongoing Clinical Trials Overview
  • Table 113: Multifocal Contact Lens - Myopia - Product Status
  • Table 114: Multifocal Contact Lens - Myopia - Product Description
  • Table 115: Multifocal Contact Lens - Presbyopia - Product Status
  • Table 116: Multifocal Contact Lens - Presbyopia - Product Description
  • Table 117: University of Washington Pipeline Products & Ongoing Clinical Trials Overview
  • Table 118: Bionic Contact Lens - Product Status
  • Table 119: Bionic Contact Lens - Product Description
  • Table 120: Solar Powered Augmented Lenses - Product Status
  • Table 121: Solar Powered Augmented Lenses - Product Description
  • Table 122: University of Western Ontario Pipeline Products & Ongoing Clinical Trials Overview
  • Table 123: Nanocomposite Hydrogel Lenses - Product Status
  • Table 124: Nanocomposite Hydrogel Lenses - Product Description
  • Table 125: Valeant Pharmaceuticals International, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 126: BLC - 001: SVS - Product Status
  • Table 127: BLC - 001: SVS - Product Description
  • Table 128: BLC - 002: SVS - Product Status
  • Table 129: BLC - 002: SVS - Product Description
  • Table 130: BLC - 003: SVS/MF/fA - Product Status
  • Table 131: BLC - 003: SVS/MF/fA - Product Description
  • Table 132: BLC - 004: Toric - Product Status
  • Table 133: BLC - 004: Toric - Product Description
  • Table 134: BLC - 005: SVS/MF - Product Status
  • Table 135: BLC - 005: SVS/MF - Product Description
  • Table 136: BLC - 006: SVS - Product Status
  • Table 137: BLC - 006: SVS - Product Description
  • Table 138: BLC - 007: MF - Product Status
  • Table 139: BLC - 007: MF - Product Description
  • Table 140: BLC - 008: Astigmatism - Product Status
  • Table 141: BLC - 008: Astigmatism - Product Description
  • Table 142: BLC - 009: Astigmatism - Product Status
  • Table 143: BLC - 009: Astigmatism - Product Description
  • Table 144: XUV - 003: Aphakia - Product Status
  • Table 145: XUV - 003: Aphakia - Product Description
  • Table 146: XUV - 004: SVS - Product Status
  • Table 147: XUV - 004: SVS - Product Description
  • Table 148: XUV - 007: MF - Product Status
  • Table 149: XUV - 007: MF - Product Description
  • Table 150: XUV - 009: SVS - Product Status
  • Table 151: XUV - 009: SVS - Product Description
  • Table 152: XUV - 010: Astigmatism - Product Status
  • Table 153: XUV - 010: Astigmatism - Product Description
  • Table 154: XUV - 011: MF - Product Status
  • Table 155: XUV - 011: MF - Product Description
  • Table 156: XUV - 012: SVS - Product Status
  • Table 157: XUV - 012: SVS - Product Description
  • Table 158: XUV - 013: SVS - Product Status
  • Table 159: XUV - 013: SVS - Product Description
  • Table 160: XUV - 014: Presbyopia - Product Status
  • Table 161: XUV - 014: Presbyopia - Product Description
  • Table 162: XUV - 015: MF - Product Status
  • Table 163: XUV - 015: MF - Product Description
  • Table 164: Visioneering Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 165: Contact Lens - Product Status
  • Table 166: Contact Lens - Product Description
  • Table 167: NaturalVue Sphere 1 Day Contact Lenses - Product Status
  • Table 168: NaturalVue Sphere 1 Day Contact Lenses - Product Description
  • Table 169: NaturalVue Toric 1 Day Contact Lenses - Product Status
  • Table 170: NaturalVue Toric 1 Day Contact Lenses - Product Description
  • Table 171: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Status
  • Table 172: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Description
  • Table 173: VTI MPC Lens - Product Status
  • Table 174: VTI MPC Lens - Product Description
  • Table 175: VISTAKON Pharmaceuticals, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 176: K-Lens - Product Status
  • Table 177: K-Lens - Product Description
  • Table 178: Yolia Health Pipeline Products & Ongoing Clinical Trials Overview
  • Table 179: TVT Device - Product Status
  • Table 180: TVT Device - Product Description
  • Table 181: Glossary

List of Figures

  • Figure 1: Contact Lenses - Pipeline Products by Stage of Development
  • Figure 2: Contact Lenses - Pipeline Products by Segment
  • Figure 3: Contact Lenses - Pipeline Products by Territory
  • Figure 4: Contact Lenses - Pipeline Products by Regulatory Path
  • Figure 5: Contact Lenses - Pipeline Products by Estimated Approval Date
  • Figure 6: Contact Lenses - Ongoing Clinical Trials
Back to Top